Systemic Delivery of microRNA‐34a for Cancer Stem Cell Therapy

Abstract

Delivered: A solid lipid nanoparticle (SLN) system was developed to deliver microRNA-34a (miR-34a) relevant for cancer stem cell (CSC) therapy into lung tissues. In miR-34a-containing SLNs (miSLNs-34a), miR-34a is protected from degradation in the serum and its cellular-transfection efficiency in vitro is increased. Thus, treatment with miSLNs-34a results in a higher probability of survival of CSC-bearing mice (see picture). As a service to our authors and readers, this journal provides supporting information supplied by the authors. Such materials are peer reviewed and may be re-organized for online delivery, but are not copy-edited or typeset. Technical support issues arising from supporting information (other than missing files) should be addressed to the authors. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.